LZ1 30mg

Acne is one of the most common epithelial diseases affecting approximately 80% of the world's population between the ages of 16 and 35. It is caused by multiple factors such as genetic predisposition and hormonal alteration including growth factor IGF-I, among others. Acne also known as acne vulgaris (acne vulgaris) is a disease that affects the skin. It is caused by multiple factors such as genetic predisposition, hormonal alteration, stress levels, skin irritation, response to medications, among others. This disease is limited to thepilosebaceous unit (hair follicle and sebaceous glands) where it acquires different degrees of severity, is clinically manifested by the appearance of comedones with a tendency to inflammation and finally cause scarring damaging self-esteem and quality of life of those who suffer it. The evolution is governed by the increase in sebum production,hyperkeratinization, follicular obstruction and increase in colonization of the bacteria Propionibacterium acnes (P. acnes), present in the skin microbiota.

LZ1 with 15 amino acid residues containing strong antimicrobial activity against bacteria pathogens of acne vulgaris including Propionibacterium acnes, Staphylococcus epidermidis and S. aureus. Especially, it exerted strong anti-P. acnes ability. The minimal inhibitory concentration against three strains of P. acnes is 4 times lower than that of clindamycin. In experimental mice skin colonization model, LZ1 significantly reduced the number of P. acnes colonized on the ear, P. acnes-induced ear swelling, and inflammatory cell infiltration. It ameliorated inflammation induced by P. acnes by inhibiting the secretion of inflammatory factors. LZ1 showed little cytotoxicity on human keratinocyte and hemolytic activity on human blood red cells. Furthermore, LZ1 was very stable in human plasma. Combined with its potential bactericidal and anti-inflammatory properties, simple structure and high stability, LZ1 might be an ideal candidate for the treatment of acne.